

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignina 22313-1450 www.uspto.gov

| APPLICATION NO. | FILING DA | ATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. | |
|---------------------------------------|------------|------------|----------------------|------------------------------|------------------|--|
| 09/998,718 | 11/01/2001 | | James A. Burke | 17400CIP (HL) | 7192 | |
| 7 | 590 0 | 09/23/2003 | | | | |
| Carlos A. Fisher | | | | EXAMI | EXAMINER | |
| ALLERGAN, INC. T2-7H | | | | FAY, ZOH | FAY, ZOHREH A | |
| 2525 Dupont Drive Irvine, CA 92612 | | | ART UNIT | PAPER NUMBER | | |
| | | | | 1614 DATE MAILED: 09/23/2003 | 10 | |

Please find below and/or attached an Office communication concerning this application or proceeding.

| | Application No. | Applicant(s) | | | | | |
|---|--|--|--|--|--|--|--|
| | 09/998,718 | BURKE ET AL. | | | | | |
| Office Action Summary | Examiner | Art Unit | | | | | |
| Ť | Zohreh Fay | 1614 | | | | | |
| The MAILING DATE of this communication app | | | | | | | |
| Period for Reply | | | | | | | |
| A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status | i6(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI | nely filed s will be considered timely. the mailing date of this communication. O (35 U.S.C. § 133). | | | | | |
| Responsive to communication(s) filed on | | | | | | | |
| · · · · · · · · · · · · · · · · · · · | · s action is non-final. | | | | | | |
| <u> </u> | | osecution as to the merits is | | | | | |
| closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. | | | | | | | |
| Disposition of Claims | | • | | | | | |
| 4)⊠ Claim(s) <u>1-25</u> is/are pending in the application. | | | | | | | |
| 4a) Of the above claim(s) <u>1-12</u> is/are withdrawn from consideration. | | | | | | | |
| <u> </u> | i) Claim(s) is/are allowed. | | | | | | |
| 6)⊠ Claim(s) <u>13-25</u> is/are rejected. | | | | | | | |
| 7) Claim(s) is/are objected to. | | | | | | | |
| 8) Claim(s) are subject to restriction and/or election requirement. | | | | | | | |
| Application Papers | · · | | | | | | |
| 9) The specification is objected to by the Examiner. | | | | | | | |
| 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. | | | | | | | |
| Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner. | | | | | | | |
| If approved, corrected drawings are required in reply to this Office action. | | | | | | | |
| 12) The oath or declaration is objected to by the Examiner. | | | | | | | |
| Priority under 35 U.S.C. §§ 119 and 120 | | | | | | | |
| 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). | | | | | | | |
| a) ☐ All b) ☐ Some * c) ☐ None of: | | | | | | | |
| 1.☐ Certified copies of the priority documents have been received. | | | | | | | |
| Certified copies of the priority documents have been received in Application No | | | | | | | |
| Copies of the certified copies of the priori application from the International Bur See the attached detailed Office action for a list of the certified copies of the priori application from the International Bur | ity documents have been receive eau (PCT Rule 17.2(a)). | d in this National Stage | | | | | |
| 14) Acknowledgment is made of a claim for domestic | • | | | | | | |
| a) ☐ The translation of the foreign language prov 15)☐ Acknowledgment is made of a claim for domestic | visional application has been rec | eived. | | | | | |
| Attachment(s) | , , , | • • | | | | | |
| 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) | 5) Notice of Informal F | (PTO-413) Paper No(s) Patent Application (PTO-152) | | | | | |
| S Patent and Trademark Office | | | | | | | |

Application/Control Number: 09/998,718

Art Unit: 1614

Claims 13-26 are presented for examination.

The response to the restriction requirement March 25, 2003 has been received and entered.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 13-25 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The claimed invention is directed to the use of "a neuroprotectant compound effective to protect the plurality of ocular neurons from cell death". The specification discloses examples of structures of some compounds within the scope of what is claimed. However, there is no evidence that there is any per se structure/function relationship between the disclosed neuroprotectant compounds and any others that might be found using the claimed method. Structural identifying characteristics of group of neuroprotectant compounds are not disclosed. Therefore, the claimed invention is not supported by an adequate written description.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Zohreh Fay whose telephone number is (703) 308-4604. The examiner can normally be reached on 9:30-6:00.

Art Unit: 1614

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel can be reached on (703) 308-4725. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4556 for regular communications and (703) 308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Z.F September 20, 2003

ZOHHZH PAY PRIMARY EXAMINER GROUP 1200